16 Mar Research Study for Adults with Chronic Cough
The purpose of this clinical research study is to look at whether the investigational study drug,
BLU-5937, works and how safe it is in adults with refractory chronic cough (RCC). This research study requires 20 visits over approximately 71 weeks. Subjects are required to wear a 24-hour cough monitor multiple times during the study.
Compensation for travel/participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire (https://www.clinicalresearchcenter.com/questionnaire/) or call 314-514-8509.
Participant Eligibility
Subjects must have persistent cough for at least one year and a diagnosis of Chronic Refractory Cough with not enough improvement after treatment for underlying health problems or for which no underlying health problems have been found out despite enough testing to determine the problem and trials of therapy.
Contact
Vicki Carmichael
(314) 514-8509 x12
Additional Study Details
Full Study Title
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
Investigator(s)
Jeffrey P. Tillinghast, MD, CPI
Barbara C. Jost, MD
Kelly A. Esposito, MSN, NP-C
Accepts Healthy Volunteers?
No
Study Site(s)
The Clinical Research Center, LLC
969 N. Mason Rd STE 240
St. Louis, Missouri 63141
